IGC PHARMA INC (IGC)

US45408X3089 - Common Stock

0.3899  -0.01 (-2.23%)

After market: 0.3837 -0.01 (-1.59%)

Fundamental Rating

1

Overall IGC gets a fundamental rating of 1 out of 10. We evaluated IGC against 195 industry peers in the Pharmaceuticals industry. IGC may be in some trouble as it scores bad on both profitability and health. IGC does not seem to be growing, but still is valued expensively.



1

1. Profitability

1.1 Basic Checks

In the past year IGC has reported negative net income.
In the past year IGC has reported a negative cash flow from operations.
IGC had negative earnings in each of the past 5 years.
IGC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

IGC has a Return On Assets of -125.56%. This is amonst the worse of the industry: IGC underperforms 84.97% of its industry peers.
Looking at the Return On Equity, with a value of -168.81%, IGC is doing worse than 69.43% of the companies in the same industry.
Industry RankSector Rank
ROA -125.56%
ROE -168.81%
ROIC N/A
ROA(3y)-84.76%
ROA(5y)-60.82%
ROE(3y)-105.88%
ROE(5y)-74.42%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

IGC has a better Gross Margin (60.04%) than 68.39% of its industry peers.
In the last couple of years the Gross Margin of IGC has grown nicely.
IGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y64.59%
GM growth 5Y84.65%

2

2. Health

2.1 Basic Checks

IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IGC has been increased compared to 1 year ago.
IGC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IGC has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -11.17, we must say that IGC is in the distress zone and has some risk of bankruptcy.
IGC's Altman-Z score of -11.17 is on the low side compared to the rest of the industry. IGC is outperformed by 77.72% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that IGC is not too dependend on debt financing.
The Debt to Equity ratio of IGC (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -11.17
ROIC/WACCN/A
WACC9.13%

2.3 Liquidity

IGC has a Current Ratio of 1.77. This is a normal value and indicates that IGC is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IGC (1.77) is worse than 69.95% of its industry peers.
IGC has a Quick Ratio of 1.16. This is a normal value and indicates that IGC is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.16, IGC is not doing good in the industry: 77.72% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.16

2

3. Growth

3.1 Past

The earnings per share for IGC have decreased by -2.51% in the last year.
Looking at the last year, IGC shows a very negative growth in Revenue. The Revenue has decreased by -15.79% in the last year.
Measured over the past years, IGC shows a very negative growth in Revenue. The Revenue has been decreasing by -23.46% on average per year.
EPS 1Y (TTM)-2.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.35%
Revenue 1Y (TTM)-15.79%
Revenue growth 3Y14.33%
Revenue growth 5Y-23.46%
Sales Q2Q%-51.43%

3.2 Future

The Earnings Per Share is expected to grow by 16.99% on average over the next years. This is quite good.
IGC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.48% yearly.
EPS Next Y52.79%
EPS Next 2Y24.52%
EPS Next 3Y16.99%
EPS Next 5YN/A
Revenue Next Year-9%
Revenue Next 2Y1.66%
Revenue Next 3Y6.48%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

IGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

IGC's earnings are expected to grow with 16.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.52%
EPS Next 3Y16.99%

0

5. Dividend

5.1 Amount

No dividends for IGC!.
Industry RankSector Rank
Dividend Yield N/A

IGC PHARMA INC

NYSEARCA:IGC (10/31/2024, 6:34:39 PM)

After market: 0.3837 -0.01 (-1.59%)

0.3899

-0.01 (-2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap29.49M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.56%
ROE -168.81%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 60.04%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.77
Quick Ratio 1.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-2.51%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y52.79%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.79%
Revenue growth 3Y14.33%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y